CIBC Investor's Edge
- Easy to use platform
- Low fees
- Student and young investor discounts
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Generex is a business based in the US. Generex stocks (GNBT.US) are listed on the OTCQB and all prices are listed in US Dollars. Its last market close was $0.053 – the same closing value as a week prior. Generex employs 15 staff and has a trailing 12-month revenue of around $692,762.
CIBC Investor's Edge
National Bank Direct Brokerage
Since the stock market crash in March caused by coronavirus, Generex's stock price has had significant negative movement.
Its last market close was $0.0001, which is 99.98% down on its pre-crash value of $0.62 and 442,900.00% down on the lowest point reached during the March crash when the stocks fell as low as $0.443.
If you had bought $1,000 worth of Generex stocks at the start of February 2020, those stocks would have been worth $1,055.89 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $0.20.
|Latest market close||$0.0001|
|52-week range||$0.0001 - $0.005|
|50-day moving average||$0.0009|
|200-day moving average||$0.0056|
|Wall St. target price||$6|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.373|
Note: The dollar amounts in the table below are in Canadian dollars.
Historical closes compared with the last close of $0.0001
|3 months (2022-12-23)||0.0001|
|6 months (2022-09-23)||-90.00%|
|1 year (2022-03-23)||-96.67%|
|2 years (2021-03-23)||-99.97%|
|3 years (2020-03-23)||-99.98%|
|5 years (2018-03-23)||-100.00%|
|Gross profit TTM||USD$2.1 million|
|Return on assets TTM||-43.84%|
|Return on equity TTM||-1772.71%|
TTM: trailing 12 months
We're not expecting Generex to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Generex stocks were split on a 7:5 basis on 25 February 2020. So if you had owned 5 shares the day before before the split, the next day you'd have owned 7 shares. This wouldn't directly have changed the overall worth of your Generex stocks – just the quantity. However, indirectly, the new 28.6% lower stock price could have impacted the market appetite for Generex stocks which in turn could have impacted Generex's stock price.
Over the last 12 months, Generex's stocks have ranged in value from as little as $0.0001 up to $0.005. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (OTCQB average) beta is 1, while Generex's is -0.0623. This would suggest that Generex's stocks have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Generex has bucked the trend.
Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.
Your guide to how ETFs work and whether this type of investment is right for you.Read more…
The best stock trading app for beginners is easy to use and offers free trades.Read more…
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.Read more…
Everything we know about the Neuraxis IPO plus information on how to buy in.
Everything we know about the Brera IPO plus information on how to buy in.
Everything we know about the TXO Energy IPO plus information on how to buy in.
Your guide to how ETFs work and whether this type of investment is right for you.
Steps to owning and managing TXG stock, with 24-hour and historical pricing before you buy.
The best stock trading app for beginners is easy to use and offers free trades.
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
An healthcare company, NFT tech developer and baby products retailer are among the IPOs expected to take place this month.
Owning a stock means you own part of a company and can potentially grow your wealth. But there is a risk of loss.
The best time to buy stocks could be right after an IPO, during expansion periods or when other investors are buying or selling.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.